12:00 AM
Jul 29, 2013
 |  BC Week In Review  |  Company News  |  Deals

Opalia Pharma S.A., Recordati deal

Recordati said it acquired 90% of branded generics company Opalia in a deal valued at about €37 million ($48.6 million). Recordati estimates Opalia will have about €18.5 million ($24.3...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >